Chief Executive Officer
Mr. Salka has served as CEO and a member of the Company’s board of directors since joining AmpliPhi in May 2015. Prior to AmpliPhi, Mr. Salka served as CEO of Aspyrian Therapeutics Inc., a company focused on developing near-infrared photoimmunotherapy (PIT) therapies. Before that, Mr. Salka was the CEO of Ambit Biosciences, which developed treatments for oncologic, autoimmune and inflammatory diseases until acquired by Daichi Sankyo in 2014. During Mr. Salka’s tenure there, he was responsible for transforming the company from a service contract business to a fully capable drug discovery and development enterprise. He has also served as the president and chief executive officer of two privately held genomics companies, Arcaris, Inc. and 454 Corporation (sold to Roche in 2007). He also previously co-founded one of the first commercial genomics companies, Sequana Therapeutics, Inc., which pioneered the effort to commercialize the international Human Genome Project. Mr. Salka has also been a board member of Sorrento Therapeutics, Inc. and San Diego State University College of Business Administration. He received his M.B.A. from Carnegie Mellon University and his B.S. in Finance from San Diego State University.
Chief Financial Officer
Mr. Martin has served as CFO since January 2016. Most recently, Mr. Martin served for three years as the CFO of Apricus Biosciences, a publicly-traded pharmaceuticals company. Prior to Apricus, he was CFO and interim CEO of BakBone Software, where he led the sale of the Company to Quest Software, and Senior Consultant to the CEO and Acting Chief Accounting Officer for Leap Communications, a $2B telecommunications company. Mr. Martin’s leadership experience also includes serving as CFO of Stratagene Corporation, sold to Agilent Technologies in 2007 for $240M and as controller for Gen-Probe, now a part of Hologic. Mr. Martin began his career at Deloitte, where he spent 10 years in the San Diego office and served as Senior Audit Manager. He is active in the San Diego community, including serving as past president of the San Diego Chapter of FEI (Financial Executives International), a committee member of the Corporate Directors Forum and as a member of the San Diego Holiday Bowl Committee. Mr. Martin holds a B.S. in Accounting from San Diego State University and is a certified public accountant.
Chief Operating Officer
Dr. Bilinsky has served as COO since January 2017. Prior to joining AmpliPhi, Dr. Bilinsky was General Manager, Immuno-Oncology and Senior Vice President, Special Operations and Research Operations at Ignyta, Inc., a biotechnology company focused on oncology precision medicines. Prior to Ignyta, he was Senior Vice President, Corporate Development at Vical, Inc., a biotechnology company developing vaccines and immunotherapies for the treatment of cancer and infectious diseases, and Vice President, Business Development and Special Operations at Halozyme Therapeutics. Dr. Bilinsky was also previously Chief Executive Officer of Androclus Therapeutics, a privately-held biotechnology company developing therapeutics for autoimmune and inflammatory diseases, which he originally joined as COO. Dr. Bilinsky previously served in positions of increasing responsibility as a management consultant, project leader and ultimately as principal in the healthcare practice of The Boston Consulting Group, where he advised companies in the biotechnology, pharmaceutical and life science industries on business strategy, operational performance and mergers and acquisitions. Prior to joining BCG, he worked in research positions at Symyx Technologies and MIT Lincoln Laboratory. Dr. Bilinsky received his B.S. degree in physics from the Moscow Institute of Physics and Technology and his Ph.D. degree in physics from the Massachusetts Institute of Technology.
Vice President of Chemistry, Manufacturing and Control
Dr. Gaidamaka brings more than 25 years in the life sciences sector to AmpliPhi in his role as Vice President of Chemistry, Manufacturing and Control. Prior to joining AmpliPhi, he served as CEO and CSO of Personalized OncoTherapeutics Inc. He has also held executive R&D, product development and quality control roles at Pharma Green LLD, Merial, Sanofi Pasteur, Bioniche Life Sciences Inc. and Biopharm JSC. Dr. Gaidamaka was previously head of the Department of Immunopharmacology & Allergology at the All-Union Research Institute of Drug Chemistry and Technology, Ukraine. He received a Ph.D. in immunology and microbiology and D.V.M from the Kharkov State Veterinary Academy, Ukraine.
Vice President of Research
Dr. Morales has served as VP of Research since 2012. Prior to joining AmpliPhi, she served as the head scientist for Special Phage Services (SPS), a private biotechnology company focused on bacteriophage therapy. AmpliPhi merged with SPS in 2012 to take advantage of SPS’ leadership position in the bacteriophage industry. She has over 12 years of industrial experience developing bacteriophages for therapeutic purposes against a variety of pathogens in the agricultural field and veterinarian and human medicine. Dr. Morales received her Ph.D. in bacteriophage therapy from the University of Technology, Sydney, Australia; an M.Sc. in Applied Molecular Biotechnology from the University of Sydney and a B.S. in Microbiology from the University of Los Andes, Bogota, Colombia.
Vice President of Regulatory Affairs and Program Management
Dr. Furr brings over a decade of integrated product development and regulatory affairs experience to this new position at AmpliPhi. Prior to joining the Company, Dr. Furr served as Senior Director of Operations at Rho, Inc., a clinical research organization, where she also held leadership roles in regulatory affairs, integrated product development, program management and medical writing. Dr. Furr’s prior experience includes providing strategic and operational support throughout all phases of clinical development, including formal interactions and negotiations with regulatory authorities as well as submission of several biologics license applications and new drug applications with the U.S. Food and Drug Administration. She received a Ph.D. from Texas A&M University where she studied bacteriophage lifecycle and lysis mechanisms, biochemistry, and biophysics.